AI health-tech start-up OpenEvidence has raised $210 million in a Series B round co-led by GV, Google’s venture arm, and Kleiner Perkins, lifting the company’s valuation to $3.5 billion—more than triple the $1 billion mark set at its previous financing in February. Founded in 2022, Miami-based OpenEvidence offers a free search engine that scans millions of peer-reviewed medical papers and delivers evidence-based answers at the point of care. The company says the tool is now used by roughly 430,000 physicians, or about 40 percent of all doctors in the United States, and supports more than 8 million consultations each month. OpenEvidence generates revenue through advertising placed alongside search results, a model the firm likens to Google’s approach. Rapid clinician adoption and the new capital have propelled co-founder and chief executive Daniel Nadler, who retains around 60 percent of the business, to billionaire status, according to Forbes.